MedTrace Logo

Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans

NCT01900340 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-07-16

No results posted yet for this study

Summary

The aim is to further establish a physiological role for GLP-1 as an endogenous satiety signal by examining the effect of the specific GLP-1 receptor antagonist exendin (9-39) on appetite and food intake in healthy male subjects.

Conditions

  • Appetite and General Nutritional Disorders

Interventions

DIETARY_SUPPLEMENT

Saline

Intravenous saline infusion and intraduodenal administration of saline via feeding tube

DRUG

Exendin 9-39

IV exendin(9-39) infusion and intraduodenal administration of saline via feeding tube

DIETARY_SUPPLEMENT

Saline

IV saline infusion and intraduodenal administration of nutrients

DRUG

Exendin(9-39) plus ID nutrient

Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Christoph Beglinger, MD · University Hospital Basel, Phase 1 Research Unit, Basel Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01900340 on ClinicalTrials.gov